ReviewDrug design, development and therapy2016
Profile of adalimumab and its potential in the treatment of uveitis.
Review in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis.BMJ open ophthalmology · 2023Pooled it
- Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.Drug design, development and therapy · 2018Pooled it
- The Role of Hydro-Kinesiotherapy After Intra-Articular Steroid Infiltration in the Management of Juvenile Idiopathic Arthritis: A Non-Randomized Observational Pre-Post Study with Parallel Groups.Journal of functional morphology and kinesiology · 2026Article
- Ocular complications in psoriasis and psoriatic arthritis.Reumatologia · 2026Review
- Advances in tumor necrosis factor-α inhibitors for the treatment of juvenile idiopathic arthritis-associated uveitis.Frontiers in immunology · 2026Review
- Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt-Koyanagi-Harada Disease.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches.Pediatric rheumatology online journal · 2021Review
- Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2021Review
- Review
- Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy.Journal of clinical medicine · 2020Article
- Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.Advanced drug delivery reviews · 2018Review
- An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Current treatment options in rheumatology · 2017Article
- Infliximab relieves blood retinal barrier breakdown through the p38 MAPK pathway in a diabetic rat model.International journal of ophthalmology · 2017Article
- Pathogenesis of Uveitic Glaucoma.Journal of current glaucoma practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Uveitis refers to the presence of intraocular inflammation, and as a strict definition compromises the iris and ciliary body anteriorly and the choroid posteriorly (the uvea). Untreated, uveitis can lead to visual loss or blindness. The etiology of uveitis can include both infectious and noninfectious (usually immune-mediated) causes, the latter of which are often mediated predominantly by Th1 CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.